MoonLake Immunotherapeutics (MLTX NASDAQ) stock market data APIs
$51.1112
2.27(4.4%)
as of September 17, 2025
Try our APIs with
free plan!
MoonLake Immunotherapeutics Financial Data Overview
Price chart is built with
Anychart
MoonLake Immunotherapeutics, a clinical stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland.
Prev. Close
51.1112
Open
53.3826
High
54.6731
Low
51.1805
52 wk Range
31.4201-61.87
Market Cap
3 382 M
Shares Outstanding
63 501 K
EPS
-0.87
Beta
1.27
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with MoonLake Immunotherapeutics (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get MoonLake Immunotherapeutics data using free add-ons & libraries
Get MoonLake Immunotherapeutics Fundamental Data
MoonLake Immunotherapeutics Fundamental data includes:
- Net Revenue:
- EBITDA: -199 040 352
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-05
- EPS/Forecast: -0.72
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
MoonLake Immunotherapeutics News
New
MoonLake Immunotherapeutics (MLTX) Q2 Net Loss Widens to US$55 Million
During the last quarter, MoonLake Immunotherapeutics reported a significant increase in net losses, with a net loss of $55 million for the second quarter, up from $24 million in the same period in 202...
Leerink Partners Reiterated a Buy on MoonLake Immunotherapeutics (MLTX)
MoonLake Immunotherapeutics (NASDAQ:MLTX) is one of the Best Stocks to Buy for the Next 3 Months According to Hedge Funds. On August 21, Leerink Partners analyst Thomas Smith reiterated a Buy rating o...
2 Small-Cap Biotech Stocks Well Positioned for a Breakout
Key Points Pulmonary sarcoidosis patients could soon get the treatment option they've been waiting for from aTyr Pharma. MoonLake Immunotherapeutics is running multiple phase 3 programs for its lead ...
Analysts Predict 17% Upside For ESML
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, an...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
